Staying the Course in Endovascular AAA Repair

The legal troubles and withdrawal of Guidant from the endovascular abdominal arotic aneurysm repair market may have cast a pall on public perception of the procedure, but competitors advancing new devices towards the market believe it just means a bigger piece of the pie for everyone.

The legal troubles and withdrawal of Guidant Corp. from the endovascular abdominal aortic aneurysm (AAA) repair market may have cast a pall on public perception of the procedure, but competitors advancing new devices towards the market believe it just means a bigger piece of the pie for everyone else. The exit of one of the top three AAA device players (the others are Medtronic Inc. , far and away the US market leader, and Cook Group Inc. , which dominates the market in Europe) was no shock to other endovascular AAA repair companies. They've always been aware of the risks of working in a market where the degree of difficulty of the technical challenges is far closer to an extreme marathon than to a cakewalk.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By 

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By 

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.